Metformin again? Atheroprotection mediated by macrophage AMPK and ATF1

Ian P Salt¹, Julia R C Nunes^{2

3}, Morgan D Fullerton^{2

3}

Affiliations

¹ Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
² Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
³ Centre for Infection, Immunity and Inflammation, Centre for Catalysis Research and Innovation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

Editorial

Ian P Salt et al. Cardiovasc Res. 2021.

. 2021 Apr 23;117(5):1233-1234.

doi: 10.1093/cvr/cvab065.

Ian P Salt¹, Julia R C Nunes^{2

3}, Morgan D Fullerton^{2

3}

¹ Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
² Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
³ Centre for Infection, Immunity and Inflammation, Centre for Catalysis Research and Innovation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

No abstract available

Comment on

Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase.
Seneviratne A, Cave L, Hyde G, Moestrup SK, Carling D, Mason JC, Haskard DO, Boyle JJ. Seneviratne A, et al. Cardiovasc Res. 2021 Apr 23;117(5):1295-1308. doi: 10.1093/cvr/cvaa171. Cardiovasc Res. 2021. PMID: 32667970 Free PMC article.